Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Famotidine orally disintegrating tablets cleared for ANDA submission by FDA in April 17 letter to Yamanouchi Pharma; firm filed citizen petition in July requesting authorization to change dosage form of J&J/Merck's Pepcid AC (1"The Tan Sheet" Aug. 7, 2000, p. 3). Pepcid AC lost exclusivity April 15. Also, agency gives green light to ANDA filing for generic nizatidine. Lachman Consultant Services filed citizen petition in April 2000 on behalf of unnamed drug maker to permit application for private label capsule form of Whitehall-Robins' Axid AR, for which exclusivity expired April 1. Leiner recently said it would not file an ANDA due to perceived lack of demand (2"The Tan Sheet" April 2, In Brief)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts